About · History

Our History

← Back to About

Furnetics has, for reasons peculiar to its subject matter, kept a quieter public record than most corporations of comparable age. The account below draws on the corporate register, the Hephaestus Group archive, and correspondence held by the founders' families. It is written in four chapters, one for each era the Company recognises internally: the Cambridge years, the Exodus, the establishment of Sükhbaatar, and the modern Renovations era. Where dates are contested we have used those that appear in the incorporation record.

Readers arriving from Ethics & Safety may find that the safety register and the annual reports referenced there date to October 2002; this page explains why that particular month.

Chapter I · 1992–2001

The Cambridge Years

Furnetics began in a converted animal-behaviour laboratory on the north side of Cambridge, funded by a small group of unusually patient investors and run in its first year by Dr. Alastair R. Vellacott and three founding partners — each of whom, at the time, could have taken a chair at any Russell Group university and chose not to. The nine years that followed were the quietest in the corporation's history — most of the work never left the bench — and, in retrospect, the most consequential. Every service line offered today traces to a paper or protocol written before the Company crossed the English Channel.

  1. March 1992

    The founding partnership is signed

    The four co-founders — Dr. Alastair R. Vellacott, then Clinical Registrar in Medical Genetics at Guy's Hospital, and three colleagues drawn from Cambridge, Basel, and Edinburgh — sign a limited-partnership agreement under the working title Furnetics. The founding prospectus commits the Company to "the medical realisation of chosen identity" and to publishing no work whose disclosure would embarrass its subjects. Vellacott is named managing partner.

  2. Autumn 1993

    The Hephaestus Group is formed as the research arm

    The founders separate long-horizon research from clinical operations into an internal division named for the smith-god who reshaped bodies to order. Hephaestus takes on the recombinant-vector programme and remains, thirty-three years later, the corporation's only wholly-internal research organisation.

  3. June 1996

    First Genetic Maintain compassionate-use trial

    Working with a partner clinic in Basel, the Company administers its first therapeutic protocol under a single-patient compassionate-use provision. The indication was an inherited connective-tissue disorder; the patient remains under structured follow-up. The protocol is retained today as the founding entry of the Genetic Maintain™ procedure class. Vellacott returns from the trial with a Basel-market kitten he names for the town. She attends every founder meeting for the following two decades and is credited by name in three Hephaestus internal reports.

  4. November 1998

    Reincorporation as Furnetics Unlimited Ltd.

    The limited partnership is reorganised as a private company limited by shares. The founders retain a controlling interest and the copyright over the corporate name; the change gives the Company standing to negotiate directly with regulators. The 1998 date is the one cited in the copyright line of every Furnetics document since.

  5. May 2000

    The Medicines Control Agency opens a review

    Following a paper delivered at a private workshop in Uppsala, the Medicines Control Agency (the predecessor of the MHRA) writes to the Company requesting a series of consultations on what it terms "the classification of your therapeutic products." Sixteen months of correspondence follow. The founders characterise the exchange, in later interviews, as courteous and entirely at cross purposes.

  6. 14 September 2001

    The Novel-Therapy Injunction

    An interim injunction issued out of the High Court, on application from the Agency, halts clinical activity in England and Wales pending "further deliberation" as to whether the Company's products constituted medicinal products, medical devices, or something for which the statute did not yet provide. The injunction was never formally lifted; it simply ceased to have any subject to enjoin once the corporation moved its clinical operations off-shore.

“There is no medical need finer than the wish to be someone else. We build for that need alone; everything else follows from it, including, unfortunately, the paperwork.”

— Dr. Alastair R. Vellacott, remarks at the Hephaestus retreat, spring 1994

Chapter II · 2001–2010

The Exodus

The nine years between the September 2001 order and the opening of the Ulaanbaatar interim laboratory are, in the founders' correspondence, referred to only as "the Exodus." No clinical work took place in the United Kingdom during the period; the Company kept a skeleton office in Cambridge to answer regulator letters and moved every active protocol, and most of its staff, to a rolling series of jurisdictions willing to receive them. It was during this decade that the Phenotype Renovations line completed its preclinical work, that the first Phenotype clients were treated at unnamed overseas sites, that the first Genotype founder cohorts were accepted under compassionate-use terms, and that the Hephaestus Group consolidated into what would become its permanent research form.

  1. October 2001

    The founders convene at Fribourg

    A private meeting of the founding partners, held at a hotel in Fribourg well away from either British or Continental press, resolves that the Company will neither contest the injunction on its merits nor accept the classification it implies. The minutes record twenty-two candidate jurisdictions for relocation; Mongolia does not appear on the initial list.

  2. Spring 2002

    Preclinical completion of the Phenotype programme

    At a satellite site outside the United Kingdom (the founders have never publicly identified the exact location) the Hephaestus Group completes the preclinical work on what will become the Phenotype Renovations™ line. The programme's principal investigator remains the only person known to have refused three separate Nobel-adjacent nominations on the grounds that publication was not permitted.

  3. October 2002

    First Phenotype Renovations procedure administered

    The line is opened to its first client on the eleventh of October 2002. This is the date from which every subsequent adverse-event figure published by the Company is measured; readers referred here from the safety record will find the same date at the head of the register.

  4. August 2004

    First commercial Phenotype client

    The Phenotype line, having operated since October 2002 under structured-follow-up terms that limited disclosure, receives its first client under standard commercial terms. Neither the client nor the specific procedure has been named at any point; the case file appears in the safety register only as PR-0007.

  5. Autumn 2004

    First Genotype founder cohort accepted

    Under a compassionate-use protocol at the overseas satellite site, the Hephaestus Group accepts three founding pairs into what will become the Morphic Wolf lineage — the first heritable-germline procedures the Company has ever performed. A seventh founder joins the cohort the following summer; the first Genotype-conceived child is born to the cohort in late 2005. Her portrait, and those of the founders, hang today in the Founders' Gallery at the Ulaanbaatar campus. The technique will not be offered under the Genotype Renovations™ name to commercial clients until 2011.

  6. Autumn 2007

    The Hephaestus Group consolidates overseas

    The Hephaestus Group, which since 2001 has operated across three overseas sites of varying permanence, consolidates its research and clinical-manufacturing work at a single unpublicised facility outside Europe. The site remains in use to this day as a redundant secondary laboratory; its existence, though not its location, is referenced in the current Independent Ethics Board charter.

  7. April 2010

    Ulaanbaatar is selected

    Following an eighteen-month legal and technical review co-led with counsel in Ulaanbaatar, Singapore, and Geneva, the founders resolve that Mongolia's 2001 Medical Technologies Act — then unique in the world in engaging seriously with advanced-therapy medicinal products on their own terms — offers the operating environment the Company requires. A Memorandum of Understanding is signed with the Ministry of Health on the fourteenth of April. Dr. Vellacott takes formal residence in Ulaanbaatar the same year.

“Regulation follows imagination. Where the two fall out of step, one has two honourable options: to slow one's imagination, or to carry it to a place whose law has kept up. We chose the second and consider it, on the evidence of the nine years since, the more difficult of the two.”

— Dr. Alastair R. Vellacott, memo to the founding partners, 2 October 2001

Chapter III · 2010–2015

Establishing Sükhbaatar

The five years that begin with the Ulaanbaatar interim laboratory and end with the relaunch of the Phenotype Renovations pipeline are the years in which Furnetics ceased to be an unusually well-funded research collective and became a corporation in the ordinary sense of the word. The permanent campus at 15 Sükhbaatar Square, opened in 2013 under Nomin Batbayar's direction, remains the operating and legal centre of the Company.

  1. September 2010

    The Ulaanbaatar interim laboratory opens; the Cambridge office closes

    Furnetics leases a four-storey building near the Ministry of Health as an interim clinical and manufacturing site. Ninety-three staff relocate from the various overseas sites of the Exodus; a further two hundred are recruited locally. The final Cambridge lease is not renewed at the end of its term.

  2. February 2011

    Nomin Batbayar joins as Chief Operating Officer

    Ms. Batbayar joins the corporation on secondment from Mongolia's Ministry of Economy, where she had led the country's foreign investment programme for medical technology since 2005. Her operating mandate is the buildout of the permanent 300,000-square-metre campus at 15 Sükhbaatar Square, together with the establishment of the corporation's manufacturing quality system.

  3. May 2011

    The Genotype Renovations line opens commercially

    The Genotype Renovations™ product line is opened for commercial client access, formalising the compassionate-use founder-cohort programme that has operated at the Hephaestus Group since Autumn 2004. Commercial oversight sits with a strictly bounded internal ethics committee pending the formal constitution of the Independent Ethics Board in 2014. The line remains the most narrowly available of the four; consult the jurisdictional matrix for current availability.

  4. October 2013

    The Sükhbaatar Square campus opens

    The permanent campus at 15 Sükhbaatar Square — three hundred thousand square metres across four connected buildings, with clean rooms to EU GMP Grade A and residential quarters for post-procedure recovery — is opened by the Minister of Health and the Chairman of the Board. It has been the corporation's registered headquarters since.

  5. June 2014

    The Independent Ethics Board is convened

    The Board is constituted, on the recommendation of the Scientific Advisory Board, as a body external to the corporation with binding veto power over procedure classes. Its first chair is drawn from the Karolinska Institute. Its charter is published concurrently and has been revised seven times since; the current revision is the one described on the Ethics & Safety page.

  6. September 2014

    Genetic Select launches

    The fourth service line — a preimplantation and pre-conception selection service developed at the request of the (then internal-only) Clinical Review Board over a period of four years — is opened. It completes the corporation's product range as it exists today.

  7. November 2015

    The Phenotype Renovations pipeline is relaunched

    Under Dr. Ines Marchetti-Roux, then Head of Sequencing R&D, the Phenotype Renovations line is re-architected around the in-vivo recombinant delivery pipeline she developed at the Institut Pasteur. The v2 architecture halves on-site clinical time and remains the current operating specification.

“We came here because we were welcome. That is a plain matter of fact and it is also, I hope, the beginning of a longer sentence in which we prove ourselves worthy of the welcome.”

— Nomin Batbayar, opening remarks at the Sükhbaatar Square campus, 12 October 2013

Chapter IV · 2016–present

The Renovations Era

The decade since the four service lines assumed their modern commercial form has been one of quiet consolidation. Staff have grown from six hundred to over three thousand, procedure counts have crossed their major thresholds without external event, and the Board's stated intention is to continue in that pattern.

  1. February 2016

    The one-thousandth procedure is administered

    The corporation crosses one thousand cumulative procedures across all four lines. Per Company practice the client is not identified.

  2. April 2017

    The Brussels Client Services Office opens

    A small office near the European Parliament is opened to provide consultation, intake, and (for Genetic Maintain™) delivery of therapeutic products to European clients under the jurisdictional matrix now published on the Ethics & Safety page. It is the corporation's second permanent site.

  3. March 2019

    Nairobi opens; Dr. Kenji Arai is appointed Chief Medical Officer

    An East African office is opened in Nairobi to serve clients on that continent under a jurisdictional review executed with the Kenya Medical Research Institute. In the same month, Dr. Kenji Arai — previously Head of Reconstructive Practice at the Ulaanbaatar campus since 2013 — is appointed Chief Medical Officer, taking over the corporation's clinical protocol authority from a founding-era interim arrangement.

  4. January 2021

    The Client Privacy Programme is formalised

    Priya Ravindran, the corporation's Deputy General Counsel since 2016, is appointed General Counsel and Chief Privacy Officer. The Client Privacy Programme — a written framework governing every touchpoint between Furnetics and its patient-clients, and the basis for the confidentiality trusts through which private-client engagements are structured — is published within her first year in the role.

  5. July 2022

    The ten-thousandth procedure is administered

    Six years after the one-thousandth, cumulative procedures cross ten thousand. Publication of the milestone in that year's annual safety report is accompanied by the corporation's first fully-anonymised aggregate outcome data set, made available on request to institutional partners and regulators.

  6. April 2025

    The Scientific Advisory Board admits its fourth seat

    Universidad de Buenos Aires joins the SAB as its fourth institutional seat, restoring the four-continent representation the Board has sought since its inception. The tenth Annual Safety Report is published in the same month.

“The interesting work now is not in what we can do — the last decade has answered that — but in what we choose to do, and for whom, and under what conditions. That is a slower question and we intend to take our time on it.”

— Dr. Kenji Arai, remarks on appointment as Chief Medical Officer, March 2019